The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

Stephin J. Vervoort, Sarah A. Welsh, Jennifer R. Devlin, +30

Cell

Cancer ResearchSignal TransductionSignaling PathwayMedicineCancer Genomics +7

Oncoprotein <scp>CIP</scp> 2A is stabilized via interaction with tumor suppressor <scp>PP</scp> 2A/B56

Jiao Wang, Juha Okkeri, Karolina Pavic, +8

EMBO Reports

Signal TransductionCell RegulationOncogenic AgentMedicineCell Biology +5

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

Otto Kauko, Susumu Y. Imanishi, Evgeny Kulesskiy, +17

Journal of Biological Chemistry

The Metastasis-Promoting Phosphatase PRL-3 Shows Activity toward Phosphoinositides

Victoria McParland, Giulia Varsano, Xun Li, +7

Biochemistry

Protein FunctionSignal TransductionSignaling PathwayBiochemistryMedicine +11

CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis

Anni Laine, Srikar G. Nagelli, Caroline Farrington, +21

Cancer Research

Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A

Karolina Pavic, Nikhil Gupta, Judit Domènech Omella, +19

Nature Communications

Molecular RegulationMolecular BiologyPp2a-b56α TrimerCancer BiologyTumor Biology +18

Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling

Farid Ahmad Siddiqui, Hanna Parkkola, Vladimir Vukić, +7

Cancers

Chemoprevention StrategyCancer BiologyTumor BiologyMolecular PharmacologySignaling Pathway +18

Interrogating PP1 Activity in the MAPK Pathway with Optimized PP1‐Disrupting Peptides

Yansong Wang, Bernhard Hoermann, Karolina Pavic, +3

ChemBioChem

Cell DeathPeptide ScienceOptimized Pp1‐disrupting PeptidesPdp-mediated Pp1 ActivationSignaling Pathway +19

An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit <i>KRAS</i> Mutant Cancer Cell Growth

Pelin Kaya, Elisabeth Schaffner‐Reckinger, Ganesh babu Manoharan, +8

Journal of Medicinal Chemistry

Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias

Eleonora Mäkelä, Karolina Pavic, Taru Varila, +11

Clinical Cancer Research